Publication:
Surgical Technology International XIX - Cardiovascular Surgery
Article title:

Latest Advances in Transcatheter Aortic Valve Implantation

Order Article:

Reprint Copies:  500 - $1,960.00

1000 - $3,720.00

By e-mail: PDF Format - $115.00

 

Author(s)

Jörg Kempfert, M.D.
Resident
Heart Center, University of Leipzig

Clinic for Cardiac Surgery, Leipzig, Germany

 

Sven Lehmann, M.D.
Consultant
Heart Center, University of Leipzig

Clinic for Cardiac Surgery, Leipzig, Germany

 

Axel Linke, M.D., Ph.D.
Consultant
Heart Center, University of Leipzig

Clinic for Cardiology, Leipzig, Germany

 

Ardawan Rastan, M.D., Ph.D.
Consultant
Heart Center, University of Leipzig

Clinic for Cardiac Surgery, Leipzig, Germany

 

Arnaud Van Linden, M.D.
Resident
Heart Center, University of Leipzig

Clinic for Cardiac Surgery, Leipzig, Germany

 

Johannes Blumenstein, M.D.
Resident
Heart Center, University of Leipzig

Clinic for Cardiac Surgery, Leipzig, Germany

 

Gerhard Schuler, M.D., Ph.D.
Chief
Heart Center, University of Leipzig

Clinic for Cardiology, Leipzig, Germany

 

Friedrich W. Mohr, M.D., Ph.D.
Chief
Heart Center, University of Leipzig

Clinic for Cardiac Surgery, Leipzig, Germany

 

Thomas Walther, M.D., Ph.D.
Consultant
Heart Center, University of Leipzig

Clinic for Cardiac Surgery, Leipzig, Germany

Abstract
Transcatheter aortic valve implantation (TAVI) is a truly minimally invasive technique allowing for off-pump aortic valve implantation in selected high-risk patients. Potential advantages are the avoidance of cardiopulmonary bypass, aortic cross-clamping, and sternotomy. Feasibility has been proven for a retrograde transfemoral, retrograde trans-subclavian, and antegrade trans-apical approach. Superiority of one of these delivery routes is as yet unproven. Given the excellent outcome following conventional aortic valve replacement even in octogenarians and the lack of prospectively randomized trials proving the effectiveness of TAVI, this new innovative technique should be restricted to selected high-risk patients at present. Nevertheless, TAVI has already evolved into a routine procedure in selected specialized centers providing a safe and reproducible treatment option for high-risk elderly patients suffering from severe symptomatic aortic stenosis.

 

 

Products featured in the Article:

 

.